Articles by Adeline Siew, PhD - BioPharm International



Articles by Adeline Siew, PhD

Shire Acquires Lotus Tissue Repair

Jan 8, 2013

Shire has signed an agreement to acquire Lotus Tissue Repair, Inc., a biotechnology company developing the first and only protein replacement therapy for the orphan disease, dystrophic epidermolysis bullosa (DEB).

Janssen and GlycoVaxyn Collaborate on Vaccine Development

Jan 7, 2013

Janssen Pharmaceuticals, Inc. and GlycoVaxyn AG have entered into a three-year agreement to collaborate on the research and development of a multivalent bacterial vaccine utilizing GlycoVaxyn's bio-conjugation technology.

Mylan Recalls Painkiller Pills Due To Risk of Higher Dosage

Dec 24, 2012

Mylan Inc. has issued a recall of three lots of the painkiller tablets, hydrocodone bitartrate and acetaminophen, USP 10 mg/500 mg, due to the potential risk that these lots (lots 3037841, 3040859 and 3042573) may exceed the potency stated on the label.

Amgen To Pay $762 Million Settlement

Dec 20, 2012

Amgen has agreed to pay a settlement of $762 million to resolve federal litigation accusing the company of inappropriately marketing the anemia treatment, Aranesp, for unapproved uses.

BASF Extends Offer Period to Acquire Pronova BioPharma

Dec 19, 2012

BASF has extended its offer period to acquire all of the issued and outstanding shares of Pronova BioPharma.

AIMM Therapeutics and Cosmo Pharmaceuticals to Develop Oral Antibodies for Gastrointestinal Diseases

Dec 19, 2012

AIMM Therapeutics and Cosmo Pharmaceuticals have entered into a strategic partnership to develop oral diagnostic and therapeutic antibodies for gastrointestinal diseases including colon carcinoma.

First Commercially-Available Mycoplasma Detection Test Accepted by FDA

Dec 19, 2012

Roche's MycoTOOL, which offers rapid detection of mycoplasms based on a polymerase chain reaction (PCR) test, has received FDA acceptance.

AET BioTech and BioXpress Therapeutics to Codevelop Adalimumab Biosimilar

Oct 30, 2012

AET BioTech and BioXpress Therapeutics have entered into an agreement to codevelop a biosimilar version of Abbott's tumor necrosis factor inhibitor monoclonal antibody adalimumab.

Novo Nordisk Expands R&D Facility in China

Sep 25, 2012

Novo Nordisk is investing $100 million to expand its R&D facilities in Beijing, China. The company estimates that the new 12,000-m2 (129,167 ft2) center will make it possible to increase the number of science employees from the current 130 to 200, with extra space available to accommodate additional future growth.



Click here